Abbott Laboratories balance sheet
At the end of its fiscal year on Dec 31, 2025, Abbott Laboratories reported total assets of $86.71B and shareholders' equity of $52.13B. That works out to a current ratio of 1.58 (current assets ÷ current liabilities), long-term debt of 0.19× shareholders' equity.
Balance sheet at each fiscal year end
| Fiscal year ended | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $52.67B | $76.25B | $67.17B | $67.89B | $72.55B | $75.20B | $74.44B | $73.21B | $81.41B | $86.71B |
| Current assets | $26.78B | $20.15B | $14.63B | $15.67B | $20.44B | $24.24B | $25.22B | $22.67B | $23.66B | $26.00B |
| Cash & equivalents | $18.62B | $9.41B | $3.84B | $3.86B | $6.84B | $9.80B | $9.88B | $6.90B | $7.62B | $8.52B |
| Current liabilities | $6.66B | $8.91B | $9.01B | $10.86B | $11.91B | $13.11B | $15.49B | $13.84B | $14.16B | $16.50B |
| Long-term debt | $20.68B | $27.21B | $19.36B | $16.66B | $18.53B | $17.30B | $14.52B | $13.60B | $12.62B | $9.90B |
| Shareholders' equity | $20.54B | $30.90B | $30.52B | $31.09B | $32.78B | $35.80B | $36.69B | $38.60B | $47.66B | $52.13B |
| Reported in | 10-K 2019 | 10-K 2020 | 10-K 2021 | 10-K 2021 | 10-K 2022 | 10-K 2023 | 10-K 2024 | 10-K 2025 | 10-K 2026 | 10-K 2026 |
Balance-sheet figures are point-in-time values on the last day of each fiscal year. Some companies (for example banks and insurers) do not present current assets and liabilities; those cells show —.
Source: SEC EDGAR XBRL company facts for CIK 1800 (raw data). Most recent filing in this dataset: 10-Q filed Apr 29, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.